RCEL

Avita Medical, Inc. (RCEL) | Rumor.io

Avita Medical

RCEL

Attention (50-day avg)0%

Attention rank (50-day avg)#1,504

Bullish sentiment (50-day avg)95%

Price to earnings ratio-6.71

Market capitalization360.9M

Earnings per share-1.44

Dividend yield (TTM)—

Revenue (annual)71.6M

Net income (annual)-48.6M

Social

What share of all stock conversation is about RCEL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 25

AVITA Medical, Inc. (RCEL) has reached a +148.6% performance milestone.
The company's stock price has crossed the +50% milestone in 77 days.
A significant purchase of $41K worth of RCEL stock was made on June 3, 2026.

Generated by AI

Sentiment

Of the messages about RCEL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +5	86.4% +4.42
Bearish	—	—	0% -5	13.6% -4.42

Aug 7

AVITA Medical ($RCEL) delivered record second-quarter results, with net revenue up 18% year-over-year and 13% quarter-over-quarter, and significantly raised its full-year outlook.
The company's strong Q2 results and raised guidance have led to a significant price increase, with $RCEL up 57% and potentially offering 300% upside.
AVITA Medical's Q2 highlights include record revenue, strong growth, and a raised outlook, making it an interesting healthcare setup with momentum building and a potential big win in the trading journey.

Generated by AI

Topics

Of the messages about RCEL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	32.03%
Announcements	—	—	100%	43.36%
Earnings	—	—	0%	1.56%
Macro	—	—	0%	12.89%
Analysts	—	—	0%	10.16%
Controversies	—	—	0%	0%

Sep 13

AVITA Medical, Inc. (RCEL) announced positive topline results from a pivotal trial evaluating the RECELL System for repigmentation of stable vitiligo lesions.
The trial demonstrated the safety and effectiveness of the RECELL System in repigmentation of stable vitiligo lesions.
AVITA Medical issued a press release on September 12, 2022, announcing the trial results, which were attached as Exhibit 99.1 to a Form 8-K filing with the SEC.

Generated by AI

Community

Of the messages about RCEL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	32.61%	14.71%
Newcomers	—	0%	67.39%	85.29%

Regulars· Aug 7

Regulars are watching $RCEL closely, with some considering holding it for the next week.
The quarterly results have led to very good patient outcomes and excellent success rates for the company's product.
$RCEL is being used in burn unit surgeries with positive results, and the company has announced participation in a major conference.

Newcomers· Aug 25

Newcomers are focusing on the potential for a short squeeze in $RCEL, with some mentioning a target price of $0.40.
There is a mix of excitement and skepticism about the potential for $RCEL to increase in value, with some users predicting a 3x-5x gain.
The performance of $RCEL is being highlighted, with one user noting a 148.6% increase in value, citing a major milestone in the company's growth.

Generated by AI

VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that its senior management will participate in the following investor conferences: Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference – Thursday, September 10, 2026 | Investor meetings with Cary Vance, President and Chief Executive Officer, and David O’Toole, Chief Financial

27d agoYahoo Finance

All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy

Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

29d agoYahoo Finance

AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases

AVITA Medical is back in focus after fair value estimates in recent models shifted from US$9.00 to US$11.06, marking a sizeable uplift in the central price target. Analysts link these updated targets to new PermeaDerm-I data, RECELL usage trends, reimbursement developments and changes to the Stedical agreements, as they reassess how AVITA Medical might scale its burn care portfolio. As you read on, you will see how these moving targets fit into the broader narrative and what to watch to stay...

1mo agoYahoo Finance

AVITA Medical: Favorable Reimbursements For Skin Wound Care (NASDAQ:RCEL)

RCEL outlook: more predictable RECELL reimbursement, RECELL GO rollout, PermeaDerm economics, and Q4 2026 breakeven target.

1mo agoSeeking Alpha

TD Cowen raises Avita Medical stock price target on PermeaDerm data

1mo agoInvesting.com

Also Discussed

Investors talking about RCEL also mention

#	Name	Attention
1	Vision Marine Technologies Inc.VMAR	0%new
2	SanJac Alpha Low Duration ETFSJLD	0%0
3	MDxHealth SAMDXH	0%0
4	Chemung Financial CorporationCHMG	0%0
5	Principal Quality ETFPSET	0%0
6	State Street My2034 Corporate Bond ETFMYCN	0%0
7	Meridian Corp.MRBK	0%0
8	Russell Investments Global Infrastructure ETFRIFR	0%0
9	ClearOne, Inc.CLRO	0.01%-0.02
10	Greif Inc. Class A Common StockGEF	0%0

Avita Medical, Inc.

Healthcare
Medical Devices

AVITA Medical, Inc. is a therapeutic acute wound care company focused on regenerative solutions for skin restoration and wound healing. Its flagship RECELL System uses a patient’s own skin cells to create a spray-on cell suspension at the point of care for the treatment of thermal burn wounds, full-thickness skin defects, and stable depigmented vitiligo lesions. The company also markets PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix, supporting surgeons and clinicians in burn care, trauma care, and reconstructive procedures. AVITA Medical serves hospitals, treatment centers, and distributors across the United States, Japan, the European Union, Australia, and the United Kingdom. Headquartered in Valencia, California, AVITA Medical specializes in technologies designed to improve wound coverage and support clinical recovery in acute care settings.

Website

Location

28159 Avenue Stanford

Valencia, CA, 91355

United States

Social

What share of all stock conversation is about RCEL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 25

AVITA Medical, Inc. (RCEL) has reached a +148.6% performance milestone.
The company's stock price has crossed the +50% milestone in 77 days.
A significant purchase of $41K worth of RCEL stock was made on June 3, 2026.

Generated by AI

Sentiment

Of the messages about RCEL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +5	86.4% +4.42
Bearish	—	—	0% -5	13.6% -4.42

Aug 7

AVITA Medical ($RCEL) delivered record second-quarter results, with net revenue up 18% year-over-year and 13% quarter-over-quarter, and significantly raised its full-year outlook.
The company's strong Q2 results and raised guidance have led to a significant price increase, with $RCEL up 57% and potentially offering 300% upside.
AVITA Medical's Q2 highlights include record revenue, strong growth, and a raised outlook, making it an interesting healthcare setup with momentum building and a potential big win in the trading journey.

Generated by AI

Topics

Of the messages about RCEL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	32.03%
Announcements	—	—	100%	43.36%
Earnings	—	—	0%	1.56%
Macro	—	—	0%	12.89%
Analysts	—	—	0%	10.16%
Controversies	—	—	0%	0%

Sep 13

AVITA Medical, Inc. (RCEL) announced positive topline results from a pivotal trial evaluating the RECELL System for repigmentation of stable vitiligo lesions.
The trial demonstrated the safety and effectiveness of the RECELL System in repigmentation of stable vitiligo lesions.
AVITA Medical issued a press release on September 12, 2022, announcing the trial results, which were attached as Exhibit 99.1 to a Form 8-K filing with the SEC.

Generated by AI

Community

Of the messages about RCEL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	32.61%	14.71%
Newcomers	—	0%	67.39%	85.29%

Regulars· Aug 7

Regulars are watching $RCEL closely, with some considering holding it for the next week.
The quarterly results have led to very good patient outcomes and excellent success rates for the company's product.
$RCEL is being used in burn unit surgeries with positive results, and the company has announced participation in a major conference.

Newcomers· Aug 25

Newcomers are focusing on the potential for a short squeeze in $RCEL, with some mentioning a target price of $0.40.
There is a mix of excitement and skepticism about the potential for $RCEL to increase in value, with some users predicting a 3x-5x gain.
The performance of $RCEL is being highlighted, with one user noting a 148.6% increase in value, citing a major milestone in the company's growth.

Generated by AI

Avita Medical

Social

Aug 25

Sentiment

Aug 7

Topics

Sep 13

Community

Regulars· Aug 7

Newcomers· Aug 25

News

AVITA Medical at Morgan Stanley conference: growth returns, costs held down

AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference

All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy

AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases

AVITA Medical: Favorable Reimbursements For Skin Wound Care (NASDAQ:RCEL)

TD Cowen raises Avita Medical stock price target on PermeaDerm data

Also Discussed

Avita Medical, Inc.

Company Information

Location

News

AVITA Medical at Morgan Stanley conference: growth returns, costs held down

AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference

All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy

AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases

AVITA Medical: Favorable Reimbursements For Skin Wound Care (NASDAQ:RCEL)

TD Cowen raises Avita Medical stock price target on PermeaDerm data

Also Discussed

Social

Aug 25

Sentiment

Aug 7

Topics

Sep 13

Community

Regulars· Aug 7

Newcomers· Aug 25